

R E M A R K S

The above amendment to Table 1 on page 6 of the specification is an obvious correction of an obvious error, since 5 total patients were involved, 4 involving "External genital" organs and 1 involving "Cervix". Therefore, the value for "Vagina" should be "0" not "9".

New claim 9 is supported by original claim 2.

New claims 10 to 13 are supported on page 4, lines 2 to 11 of the specification.

New claim 14 is supported in the specification on page 4, lines 6 to 7.

New claims 15 and 16 are supported on page 6, lines 6 to 9.

New claims 17 to 19 are supported by table 2 on page 7 of the specification.

It is noted that applicants did not receive a reply to the REQUEST FOR COPIES OF CITED REFERENCES AND REDATED OFFICE ACTION filed November 3, 1997.

Claims 1 to 8 were rejected under 35 USC 112, second paragraph for the reasons set forth in the second paragraph on page 2 of the Office Action.

The claims were amended to avoid the 35 USC 112 rejection.

It is respectfully submitted that the present claims comply with all the requirements of 35 USC 112.

Claims 1 to 2 were rejected under 35 USC 102 as being anticipated by applicants' alleged acknowledgement of POLYPHENON<sup>TM</sup> or POLYPHENON E<sup>TM</sup> at pages 3 and 4 of the present specification for the reasons set forth in the paragraph bridging pages 2 and 3 of the Office Action.

Claims 1 and 2 were rejected under 35 USC 102 as being anticipated over Liao et al. USP 5,605,929 for the reasons set forth on page 3, lines 3 to 5 of the Office Action.

Claims 1 to 4 were rejected under 35 USC 103 as being obvious over Liao et al. for the reasons set forth beginning at the bottom of page 3 and continuing to the bottom of page 4 of the Office Action.

The above rejections under 35 USC 102 and 35 USC 103 are moot in view of the present claims.

Method claims 5 to 8 were not included in the prior art. During a telephone interview with the Examiner on October 29, 1997, the Examiner said that claims 5 to 8 were free of any prior art rejection.

Liao et al. concern inhibiting 5 $\alpha$ -reductase activity (for treatment of prostatic hyperplasia, prostate cancer, hirsutism, acne, male pattern baldness, seborrhea and other diseases related to androgen hyperactivity).


Liao et al. is silent with respect of treating HIV-infected Condyloma acuminata caused by human papillomavirus, which is the aim of applicants' claimed invention.

It is respectfully submitted that the presently claimed invention is patentable over the cited prior art.

Reconsideration is requested. Allowance is solicited.

If the Examiner has any comments, questions, objections or recommendations, the Examiner is invited to telephone the undersigned at the telephone number given below for prompt action.

Respectfully submitted,

A handwritten signature in dark ink, appearing to read 'Richard S. Barth', written over a horizontal line.

RICHARD S. BARTH  
REG. NO. 28,180

FRISHAUF, HOLTZ, GOODMAN, LANGER & CHICK, P.C.  
767 THIRD AVENUE - 25TH FLOOR  
NEW YORK, NEW YORK 10017-2023  
Tel. No. (212) 319-4900  
Fax No. (212) 319-5101  
RSB/jh